<DOC>
	<DOC>NCT01631864</DOC>
	<brief_summary>This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and oxidative metabolism in obese hypertensive subjects.</brief_summary>
	<brief_title>Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Written informed consent must be obtained before any study assessment is performed. Males and females of nonchildbearing potential ≥ 18 years of age. Subjects with mild to moderate essential hypertension, Untreated subjects must have a mean seated SBP (msSBP) ≥ 130 mmHg and &lt; 180 mmHg at screening. Pretreated subjects must have a msSBP ≤ 160 mmHg at screening and &lt; 180 mmHg at the end of the washout period. Waist circumference ≥ 102 cm (men) and ≥ 88 cm (women); Exclusion criteria: Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives of enrollment, whichever is longer; or longer if required by local regulations. History of angioedema, drugrelated or otherwise History of hypersensitivity to LCZ696, amlodipine, or drugs of similar chemical classes. Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥ 180 mmHg) at screening or at the end of the washout period. Type 1 or Type 2 diabetes mellitus. Dyslipidemia requiring pharmacological therapy with a fibrate or nicotinic acid. Concomitant use of antihypertensives, antidiabetics, or drugs with effects on glucose or lipid metabolism for the duration of the study. Other protocol defined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hypertension, obesity, insulin sensitivity, lipolysis, LCZ696</keyword>
</DOC>